Products for Research Use Only
RegisterLogin

Ligustroflavone

CAT: 0804-HY-N0546-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N0546-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis[1][2][3].
CAS Number
260413-62-5
Product Name Alternative
Nuezhenoside
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
CaSR; Mixed Lineage Kinase; RIP kinase; TGF-beta/Smad
Type
Natural Products
Related Pathways
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt; TGF-beta/Smad
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology; Metabolic Disease; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ligustroflavone.html
Purity
99.90
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C=C(C1=CC=C(O)C=C1)OC2=CC(O[C@H](O[C@H](CO[C@H](O[C@@H](C)[C@H](O)[C@H]3O)[C@@H]3O)[C@@H](O)[C@@H]4O)[C@@H]4O[C@@](O[C@@H](C)[C@H](O)[C@H]5O)([H])[C@@H]5O)=C6)C2=C6O
Molecular Formula
C33H40O18
Molecular Weight
724.66
Precautions
H302, H315, H319
References & Citations
[1]Feng R, et al. Protective Effects of Ligustroflavone, an Active Compound from Ligustrum lucidum, on Diabetes-Induced Osteoporosis in Mice: A Potential Candidate as Calcium-Sensing Receptor Antagonist. Am J Chin Med. 2019;47 (2) :457-476.|[2]Zhang YY, et al. Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway. Naunyn Schmiedebergs Arch Pharmacol. 2019 Sep;392 (9) :1085-1095.|[3]Kang R, et al. Ligustroflavone ameliorates CCl4-induced liver fibrosis through down-regulating the TGF-β/Smad signaling pathway. Chin J Nat Med. 2021 Mar;19 (3) :170-180.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Isoform
RIPK1; RIPK3

Alternative Products

CatalogName
TB0446-0100Ligustroflavone
A14679-25Ligustroflavone 25mg
371646Ligustroflavone discontinued
A14679-10Ligustroflavone 10mg
A14679-50Ligustroflavone 50mg
A14679-5Ligustroflavone 5mg

Popular Products